Nutriband Announces Upcoming Preferred Stock Dividend Details

Author: Owen Jenkins Updated: 07-18-2025 09:49 AM

Nutriband's Dividend Announcement for Preferred Stock Holders

Nutriband Inc. (NASDAQ: NTRB, NTRBW) is making waves with an exciting update for its shareholders regarding the upcoming 25% preferred stock dividend. This announcement is crucial for individuals holding shares and captures their attention as key dates approach.

Key Dates to Remember

Shareholders on record as of July 25 will soon receive a preferred share for every four shares of common stock that they own. This substantial dividend payout highlights the company's dedication to enhancing shareholder value. The official pay date for these preferred shares will be August 5, giving investors crucial insight into when they can expect their rewards.

Conversion of Preferred Shares

Each preferred share distributed will allow for conversion into a single share of common stock, contingent upon the FDA’s approval of Nutriband's groundbreaking AVERSA Fentanyl product. This conversion offers a strategic advantage for investors who anticipate strong performance from Nutriband's innovative offerings.

Dividend Rights for Preferred Shares

Should the new preferred shares remain unconverted, they will entitle holders to a cash dividend, which will be paid out from the company's profits on an annual basis, subject to the discretion of the board of directors. This reinforces Nutriband's commitment to providing ongoing returns to its investors, even if conversion does not occur.

About AVERSA™ Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology represents a significant innovation in pain management solutions. By integrating aversive agents into transdermal patches, this technology aims to combat abuse, diversion, misuse, and unintended exposure to potentially harmful drugs. The potential impacts of AVERSA™ technology are essential for ensuring that vital medications, especially fentanyl, remain accessible to patients who genuinely need them.

Company Overview

Nutriband Inc. is at the forefront of developing transdermal pharmaceutical products. Their lead product focuses on an abuse-deterrent fentanyl patch, leveraging the advantages of AVERSA™ technology. This technology can be crucial in the fight against drug abuse, addressing a significant healthcare challenge by preventing misuse while ensuring legitimate access for patients.

Contact Information

For more information, Nutriband invites inquiries through their phone at 407-377-6695 or email at info@nutriband.com. Their dedication to transparency and investor relations is reflected in their proactive communication.

Frequently Asked Questions

What is the preferred stock dividend announced by Nutriband?

Nutriband announced a 25% preferred stock dividend, with shareholders receiving preferred shares based on their common stock ownership.

When will the preferred stock dividend be paid?

The pay date for the preferred stock dividend is set for August 5.

What is the significance of the preferred shares?

Preferred shares will be convertible into common stock upon FDA approval of Nutriband's AVERSA product, enhancing their value for investors.

What is AVERSA technology?

AVERSA™ is an innovative abuse-deterrent transdermal technology designed to prevent misuse of certain pharmaceutical products, such as fentanyl patches.

How can shareholders contact Nutriband for more information?

Shareholders can contact Nutriband via phone at 407-377-6695 or email info@nutriband.com for inquiries and updates.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.